India initiates probe against China’s alleged dumping of vitamin C

India has initiated a probe into the alleged dumping of Vitamin C, used by pharmaceutical firms for the production of medicines, from China following a complaint by a domestic manufacturer.

NEW DELHI: India has initiated a probe into the alleged dumping of Vitamin C, used by pharmaceutical firms for the production of medicines, from China following a complaint by a domestic manufacturer.

Bajaj Healthcare Ltd has filed the application before the commerce ministry’s investigation arm DGTR, seeking initiation of the probe.
The company alleged that the domestic industry is impacted due to the dumping of Vitamin C from China PR and has requested for the imposition of anti-dumping duty on the imports, according to the notification of the Directorate General of Trade Remedies (DGTR).

Advertisement

The company alleged that the domestic industry was affected by China PR’s dumping of Vitamin C and requested the imposition of anti-dumping duty on imports, according to a notification from the Directorate-General for Trade Remedies (DGTR).

Bajaj Healthcare is one of India’s largest manufacturers of vitamin C, which is ascorbic acid, as well as its derivatives. In its investor presentation last month, the company listed Sun Pharmaceutical Ltd, Pfizer Ltd, Abbott Healthcare, and GlaxoSmithKline Pharmaceuticals among its top clients for active pharmaceutical ingredients in the domestic market.